Our lead candidate, Pritumumab (PTB), is a monoclo
Post# of 24955
(Total Views: 106)
Posted On: 05/04/2022 2:12:45 PM
Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that will be studied in Phase I clinical trials for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 is being researched.
www.nascentbiotech.com
www.nascentbiotech.com
(0)
(0)Scroll down for more posts ▼